Isis Pharmaceuticals To Provide Update On Its Metabolic Franchise
CARLSBAD, Calif., Dec. 3, 2012 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will highlight three drugs from Isis’ metabolic franchise in a conference call and webcast on Friday, December 7, 2012 at 12:00 p.m. Eastern Time. This call will be archived for a limited time on Isis’ Web site.
In this call, Isis will highlight three drugs, ISIS-PTP1B(Rx), ISIS-GCGR(Rx) and ISIS-GCCR(Rx), from its metabolic franchise, and discuss the potential therapeutic context for each drug in the treatment paradigm for patients with type 2 diabetes.
At 12:00 p.m. Eastern Time, Friday, December 7, 2012, Isis will conduct a live webcast and conference call. Interested parties may listen to the call by dialing 1-866-362-4831, or 1-617-597-5347 for international callers, and refer to passcode “ISIS 2012.” The webcast can be accessed at wwww.isispharm.com. A webcast replay will be available for a limited time at the same address.
ISIS’ METABOLIC FRANCHISE
Isis is pursuing the discovery and development of antisense drugs to treat metabolic diseases, such as diabetes. According to the Centers for Disease Control and Prevention, diabetes affects more than 25 million people in the U.S. Isis has three drugs in its pipeline to treat type 2 diabetes, each of which acts upon targets in the liver or fat tissue through distinct mechanisms to improve insulin sensitivity, reduce glucose production, or affect other aspects of metabolic disease. Isis is developing other drugs aimed at other types of metabolic diseases.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis’ partner, Genzyme, plans to commercialize Isis’ lead product, KYNAMRO(TM), in the United States and Europe following regulatory approval. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
ISIS’ FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis’ metabolic pipeline. Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. KYNAMRO(TM) is a trademark of Genzyme Corporation.
SOURCE Isis Pharmaceuticals, Inc.